Order calls on federal government to relax restrictions on psychedelics, including ibogaine, for potential treatments.

WASHINGTON, April 18 (Reuters) - U.S. President Donald Trump signed an executive order on Saturday intended to speed up access to medical research and treatment based on psychedelic ‌drugs. The order ...

FILE PHOTO: U.S. President Donald Trump signs an executive order encouraging more research into ibogaine, next to U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., Joe Rogan, and ...

President Donald Trump has signed an executive order aimed at speeding up research and access to psychedelic drugs as potential treatments for serious mental health conditions. The move directs ...

The Trump administration has fast-tracked research into psychedelics, and experts say it is likely a matter of time before ...

President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research ...

[L.-R., standing] NIH Director Jay Bhattacharya, MD, PhD; FDA Commissioner Martin A. Makary, MD, MPH; and Robert F. Kennedy Jr., Secretary of Health and Human Services, join in applauding President ...

The executive order notes that more than 14 million American adults now suffer from serious mental illness, a large rise from a decade ago. Trump’s executive order instructs the Food and Drug ...

By Kamal Choudhury and Christy Santhosh May 18 (Reuters) - U.S. President Donald Trump's executive order to accelerate psychedelic drug development has raised hopes among companies developing the ...

President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs ...